KOVALTRY

Product Overview

About KOVALTRY

KOVALTRY is a recombinant antihemophilic factor, specifically designed to treat and manage bleeding episodes in individuals with hemophilia A. This medication is a replacement for the clotting factor VIII, which is deficient or deficiently functioning in people with this condition.

Key Benefits & Uses

• Treatment and management of bleeding episodes in individuals with hemophilia A
• Prevention of bleeding in surgical procedures and other invasive medical procedures
• Prophylaxis to prevent bleeding episodes in individuals with hemophilia A

Active Ingredient & Action

KOVALTRY contains ANTIHEMOPHILIC FACTOR (RECOMBINANT), a recombinant DNA-derived antihemophilic factor. This active ingredient works by replacing the deficient or deficiently functioning clotting factor VIII in individuals with hemophilia A, thereby facilitating the formation of blood clots and stopping or preventing bleeding episodes.

Important Notes

It is essential to follow the prescribed dosing regimen and administration instructions provided by your healthcare provider. KOVALTRY should be used under the guidance of a qualified healthcare professional. Patients should be monitored for signs of hypersensitivity reactions, such as anaphylaxis, and other adverse effects. If you have any questions or concerns, consult your healthcare provider or pharmacist for further guidance.